Mark Samuels, the chief executive of the British Generic Manufacturers Association (BGMA), described the first wave of generic weight-loss medicines as a potentially transformative opportunity for public health
Good choices include: Greek yogurt with berries and a drizzle of honey, protein pudding made from protein powder and Greek yogurt, cottage cheese with cinnamon and stevia, quality protein bars that taste like dessert, protein mug cakes, or small portions of high-protein ice cream brands
They skip the post-approval marketing, branded packaging, sales force, and manufacturer overhead that pushes Wegovy and Zepbound list prices over $1,000 per month

Understanding Tirzepatide: What It Is: Dual GIP/GLP-1 receptor agonist First-in-class medication combining two mechanisms Activates both GIP and GLP-1 receptors Produces superior weight loss to single-agonist medications Half-life of approximately 5 days (allows once-weekly dosing) Brand Names: Zepbound: Indication: Chronic weight management in adults with obesity or overweight with comorbidities FDA Approval: November 2023 Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly) Manufacturer: Eli Lilly Cost: $1,069/month Mounjaro: Indication: Type 2 diabetes management FDA Approval: May 2022 Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly) Manufacturer: Eli Lilly Cost: $1,069/month Note: Identical to Zepbound, prescribed off-label for weight loss Compounded Tirzepatide: Source: FDA-registered compounding pharmacies Indication: Prescribed for weight loss by licensed providers Doses: Custom concentrations available Cost: $349-$699/month Same active ingredient as Zepbound/Mounjaro Why Tirzepatide Is More Effective: Dual Mechanism: GLP-1 Effects (Same as Semaglutide): Appetite suppression through brain receptors Slowed gastric emptying Increased insulin secretion Decreased glucagon production Additional GIP Effects: Enhanced insulin response beyond GLP-1 alone Improved insulin sensitivity in tissues Effects on fat metabolism and energy expenditure Synergistic appetite reduction Additional weight loss mechanisms Result: The combination produces 5-7% more weight loss than GLP-1 agonists alone

The prescribing provider chooses the brand that matches the approved indication and the patient's coverage
Spreading your food intake across balanced meals throughout the day keeps L-cells more consistently active